er of OralDNA, commented, "We are
very excited to be working with Interleukin Genetics and adding the PST(R)
Genetic Test to our portfolio of diagnostic tests performed in our new U.S.
based laboratory. We believe that by combining our MyPerioPath test, which
identifies specific pathogenic bacteria causing an infection within the gum
structure, with the PST(R) Genetic Test, we are providing the dental
community with the proper tools to identify and treat periodontal disease.
The combination of both tests creates a systematic way to track and
maximize clinical outcomes for dental professionals and their patients. As
we continue to understand the systemic link and risk factors associated
with periodontal disease, it's important that we partner with companies
who, like us, are focused on helping dental professionals identify and
treat disease at its earliest onset."
About Periodontal Disease in the United States
Periodontal (gum) diseases, including gingivitis and periodontitis, are
serious infections that, left untreated, can lead to tooth loss.
Periodontal disease is a chronic bacterial infection that affects the gums
and bone supporting the teeth. Periodontal disease is usually first
diagnosed by the patients' dentist. About a third of adults will have at
least 3 to 4 teeth affected with moderate periodontal disease. Severe or
rapidly progressing disease affects 5 - 15 percent of the population. There
are over 160,000 dentists in the U.S. who frequently perform diagnostic (86
percent) and preventive (79 percent) procedures. Over half of the
population visits a dentist, usually twice a year. As a result, the average
dental office sees approximately 4,000 patients each year and many of which
will go on to develop periodontal disease. The U.S. dental market is valued
at $70 - $96 billion annually with the average patient spending about $560
per year, over half of this on diagnostic and preventive procedures. Of the
128 million patients who visit a dentist
'/>"/>
SOURCE Interleukin Genetics, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related biology technology :1.
Interleukin Genetics Announces Conference Call and Webcast to Discuss Second Quarter 2008 Business Results2.
Interleukin Genetics to Present at 2008 BIO International Convention3.
Interleukin Genetics to Present at the 13th International Conference on Periodontal Research4.
Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA)5.
Interleukin Genetics to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference6.
Interleukin Genetics Announces Conference Call and Webcast to Discuss First Quarter 2008 Business Results7.
Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer8.
Interleukin Genetics Announces Conference Call and Webcast to Discuss Fourth Quarter and Year End 2007 Business Results9.
Interleukin Genetics Retains Top Life Science Communications Firms10.
Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor11.
Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock